Please login to the form below

Not currently logged in
Email:
Password:

medicines value

This page shows the latest medicines value news and features for those working in and with pharma, biotech and healthcare.

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

Unruffled by ‘outlier’ claims, Vertex CEO upbeat on Orkambi breakthrough

cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... to capture the full value of specialist medicines for small populations.

Latest news

More from news
Approximately 2 fully matching, plus 124 partially matching documents found.

Latest Intelligence

  • The first, my last, my everything The first, my last, my everything

    This growing empowerment arguably has its biggest impact in the arena of high-value medicines. ... The patient voice is increasingly being used to influence payers and encourage them to support high-value medicines.

  • The Orkambi blame game The Orkambi blame game

    on the cost and value of the drug, which has a list price of £104, 000 ($136, 000) per patient per year. ... is to capture the full value of specialist medicines for small populations.

  • #OrkambiNow? #OrkambiNow?

    per patient per year price – comparable to the cost of older and less effective CF medicines such as Pulmozyme. ... New models urgently needed. It’s widely acknowledged that healthcare systems and the industry need to converge around new models,

  • The UK’s new five-year pricing agreement The UK’s new five-year pricing agreement

    Value assessment. More and faster NICE appraisals for new medicines including speeding up the appraisal of non-cancer medicines to be in line with cancer medicine appraisals – cost-effective new medicines ... Commercial arrangements. Opportunities for

  • Deal Watch October 2018

    Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Sandoz’s US business has retained its biosimilars, value‐added medicines and complex generics, including the ophthalmology products.

More from intelligence
Approximately 1 fully matching, plus 43 partially matching documents found.

Latest appointments

  • Redx poaches AstraZeneca senior executive Redx poaches AstraZeneca senior executive

    grow this company into a very excising and meaningful entity that has the potential to create both important new medicines for patients and generate significant value for shareholders.".

  • Sanofi appoints Dr Yong-Jun Liu as head of research Sanofi appoints Dr Yong-Jun Liu as head of research

    April. In his new role, Dr Liu will be responsible for all of the Paris-based pharmaceutical company's research and will be tasked with delivering innovative and high-value medicines.

  • ABPI Scotland appoints Sandra Auld as director ABPI Scotland appoints Sandra Auld as director

    the access to and use of new and innovative medicines for Scottish patients. . ... The ABPI Scotland team is fully committed to working with all of our stakeholders to support a common understanding and appreciation of the life-saving and life-enhancing

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics